EQRx Taps Zeitgeist, Raises $200m For Innovative Drugs at Aggressive Low Prices

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Happy (Belated) Independence Day! Timmerman Report is Here to Stay
Like the TR? Tell a Friend to Subscribe, and Enter to Win a T-Shirt
Ember Therapeutics, After Shutting Down, Pools IP With Mariel
Third Rock’s Obesity Hopeful, Ember Therapeutics, Closes Down